HepatoAI LFA : Machine-Learning-Assisted Nano-enhanced Point-of-Care System for Personalized Precise Diagnosis of Hepatocellular Carcinoma
Nano Letters · 2026
DOI: 10.1021/acs.nanolett.5c05256 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nano Letters, 2026. Verfasst von Wanchao Zuo und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural Medicines, School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Machine Learning, Point-of-Care Systems. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Early diagnosis significantly improves survival rates for hepatocellular carcinoma (HCC), yet traditional methods face limitations, including specialized instruments/personnel and prolonged reporting cycles. While lateral flow immunoassay (LFA) offers a promising alternative, its sensitivity and accuracy remain challenged. Here, we present HepatoAILFA, a machine-learning-assisted nano-enhanced point-of-care system that enables sensitive biomarker detection and digitalized, personalized HCC risk assessment. Taking enzyme-engineered metal-polydopamine frameworks as nanoprobes, a visually amplified LFA is developed for picogram-level detection of α-fetoprotein (AFP) and des-γ carboxyprothrombin (DCP). To assist LFA diagnosis, a machine-learning-based diagnostic model termed F4-ASAD is constructed by incorporating AFP, DCP, and two key predictors, age and sex. End-users input age, sex, and biomarker concentrations into a self-developed F4-ASAD-based online calculator via a smartphone to instantly obtain the HCC risk probability. This integrated system achieves 91.1% accuracy, 93.3% sensitivity, and 86.7% specificity, showing significant potential to streamline clinical workflows and advance precise disease diagnosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Natural Medicines, School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
- Zhanjiang Institute of Clinical Medicine, Guangdong Medical University Zhanjiang Central Hospital, Zhanjiang 524045, China.
- MOE Joint International Research Laboratory of Animal Health and Food Safety, Key Laboratory of Animal Bacteriology, Ministry of Agriculture, College of Veterinary Medicine, Nanjing Agricultural University, Nanjing 2100…
ORCID-Profile: Donghui Zhang, Yanmin Ju
Förderung
- National Key R&D Program of China
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
- Project Program of State Key Laboratory of Natural Medicines (China Pharmaceutical University)
- Postgraduate Research & Practice Innovation Program of Jiangsu Province
- National Key Research and Development Program of China
Zitieren
APA
Zuo, W., Meng, X., Zeng, S., Wei, W., Yang, Q., Song, J., Hu, Q., Deng, S., Zhang, D., Dai, J., & Ju, Y. (2026). HepatoAI LFA : Machine-Learning-Assisted Nano-enhanced Point-of-Care System for Personalized Precise Diagnosis of Hepatocellular Carcinoma. Nano Letters. https://doi.org/10.1021/acs.nanolett.5c05256
Vancouver
Zuo W, Meng X, Zeng S, Wei W, Yang Q, Song J, et al. HepatoAI LFA : Machine-Learning-Assisted Nano-enhanced Point-of-Care System for Personalized Precise Diagnosis of Hepatocellular Carcinoma. Nano Letters. 2026. doi:10.1021/acs.nanolett.5c05256
BibTeX
@article{Zuo2026,
author = {Zuo, Wanchao and Meng, Xiangming and Zeng, Siqi and Wei, Wenlu and Yang, Qing and Song, Jiaren and Hu, Qiannan and Deng, Shuyue and Zhang, Donghui and Dai, Jianjun and Ju, Yanmin},
title = {HepatoAI LFA : Machine-Learning-Assisted Nano-enhanced Point-of-Care System for Personalized Precise Diagnosis of Hepatocellular Carcinoma},
journal = {Nano Letters},
year = {2026},
doi = {10.1021/acs.nanolett.5c05256}
}
EUVIMED